SPPI - Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

• Spectrum Pharmaceuticals ( NASDAQ: SPPI ) stock jumped 10.4% afterhours on Friday after the U.S. Food and Drug Administration approved its Rolvedon injection .
• The injection is used to treat chemotherapy-induced neutropenia (abnormally low count of a type of neutrophils).
• SPPI said the FDA's nod marks the first novel long-acting GCSF (LA-GCSF) product approval in over 20 years.
• The company plans to commercially launch the injection in Q4.
• Shares of SPPI have fallen 18.2% YTD.

For further details see: